On the other hand, the enrichment of CD44+CD24−/low M-CSCs may contribute to the highly aggressive clinical behavior of the basal/cHER2+ phenotype since CD44+CD24−/low cells will endow this subtype with a mesenchymal-related enhancement of BC progression [85-87]. Here, CD24 is linked to breast cancer.